


Synthesis of Polysubstituted Pyrroles via Pd-Catalyzed Oxidative Alkene C–H Bond Arylation and Amination

Jia Zheng, Liangbin Huang, Chuyu Huang, Wanqing Wu, and Huanfeng Jiang*

School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510640, China

Supporting Information


ABSTRACT: A novel Pd(II)-catalyzed oxidative approach to construct polysubstituted pyrroles from *N*-homoallylicamines and arylboronic acids was developed. This transformation is supposed to proceed through cascade formation of C–C and C–N bonds via oxidative arylation of unactive alkenes, followed by intramolecular aza-Wacker cyclization.




Transition metal-catalyzed oxidative coupling reactions have emerged as one of the most powerful tools for the efficient construction of C–C and C–heteroatom bonds.^{1,2} Among them, the Pd-catalyzed oxidative Heck reactions have drawn increasing attention of synthetic chemists due to the easy accessibility of starting materials such as arylboronic acids, alkenes and the utility of various products.² In 1975, Richard F. Heck reported the first example of oxidative Heck reaction of organoboron reagents with alkenes bearing an electron-withdrawing group.³ Subsequently, the groups of Larhed, Gaunt, Sigman, Hou et al. reported various carbon nucleophile–metal species can undergo oxidative coupling with activated alkenes, such as styrenes, 1,3-dienes, strained cyclic olefins.^{4–6} However, there are only limited examples about the oxidative Heck reactions with corresponding nonactivated olefins.^{7–9} Two strategies are usually employed to increase the propensity of coordination of nonactivated olefins to Pd center and induce reactivity, thus removing the requirement of activated olefins for oxidative Heck reactions. One pathway is utilizing ligands to adjust the steric and electronic property of metal catalysts.⁸ The other pathway is incorporating a functional group to nonactivated olefin, such as OH, NH_{Boc}, etc., which can coordinate to the Pd center (Scheme 1).⁹ Lei and Sigman recently reported respectively an oxidative Heck reaction between arylboronic acids and allylic alcohols to afford aryl ketones and aldehydes through selective β-H elimination.^{9a,b} In 2011, Zhu et al. found that arylated homoallylic alcohols were obtained via a hydroxyl group assisted Pd-catalyzed oxidative Heck reactions of boronic acids with homoallylic alcohols.^{9c} A corresponding oxidative arylation of protected-allylamines was reported by Xu and co-workers in 2013.^{9d} The group of Larhed reported a Heck/Suzuki domino diarylation reaction by using chelating vinyl ethers.^{9e} Herein, we report an oxidative cascade reaction that was initiated by the Pd-catalyzed oxidative Heck reactions with homoallylic amines and phenylboronic acids, followed by the oxidative amination processes.

Scheme 1. Pd-Catalyzed Oxidative Coupling between *N*-Homoallylic Amines and Aromatic Boronic Acids

Previous work: Pd-catalyzed oxidative coupling between arylboronic and functional alkenes



This work: Pyrrole synthesis via Pd-catalyzed oxidative Heck/oxidative amination cascade



Pyrrole skeleton frequently occurs in naturally and synthetically bioactive products as well as top-sold marketing medicines.¹⁰ For example, COX-2 isoenzyme inhibitors, Zomepirac and Fludioxonil are used extensively in pharmaceuticals (Figure 1). Therefore, the development of efficient methods to access these privileged molecules is of significant importance.¹¹ As our persistent attention on Pd-catalyzed oxidative functionalization of electronically unbiased alkyl olefins,¹² various polysubstituted pyrroles were synthesized in good to excellent yields from easily prepared homoallylic amines and commercially available arylboronic acids in one-pot transformations, using Pd(II) catalyst system.

Received: October 21, 2014

Published: December 23, 2014






Figure 1. Examples of bioactive pyrroles.

Initially, using PdCl_2 as the catalyst, *N*-(but-3-en-1-yl)-4-methylaniline (**1a**) and phenylboronic acid (**2a**) were selected as model substrates to optimize the reaction conditions. As shown in Table 1, decomposition was observed when CuCl_2 , DDQ or BQ were used, only Cu(OAc)_2 gave 33% yield (Table 1, entries 1–4). As for the selection of solvent, no desired product was detected when DMSO, DMF was selected as the solvent. Toluene and 1,4-dioxane gave relatively lower yields than that of CH_3CN (Table 1, entries 5–8). Further investigation showed that Et_3N was the best additive in comparison with *t*-BuOLi, PivOH, HOAc, DABCO and DBU (Table 1, entries 9–17). Compared with Pd(OAc)_2 and Pd(TFA)_2 , PdCl_2 exhibited better reactivity (Table 1, entries 18–19). When this reaction proceeded at 50 °C, only 42% of product was obtained (Table 1, entry 20). Thus, the standard conditions were obtained as PdCl_2 (10 mol %), Cu(OAc)_2 (3 equiv), Et_3N (2 equiv), in CH_3CN at 80 °C.

The scope of this reaction was explored as the optimized conditions identified. A range of substituted phenylboronic acids were initially surveyed (Table 2). Both electron-donating and -withdrawing groups were tolerated in this cascade reaction. A variety of *para*-substituted functional groups, such as alkyl, phenyl, halogen and ester were compatible to obtain desired pyrroles **3ab**–**3ag** in moderate to good yields. The *meta*- and *para*-substituted substrates led to good yields of the

Table 2. Substrate Scope of Phenylboronic Acids^{a,b}

^aReaction conditions: **1a** (0.1 mmol), **2** (0.15 mmol), PdCl_2 (10 mol %), Et_3N (2 equiv) and Cu(OAc)_2 (3 equiv) in 1 mL CH_3CN at 80 °C for 12 h. ^bIsolated yield. ^cThe reaction was stirred for 24 h.

corresponding products (**3ah**, **3ai**). The naphthylboronic acid also proceeded smoothly with **1a** to afford 88% yield of product

Table 1. Optimization of Reaction Conditions^a


entry	catalyst	oxidant	additive	solvent	yield (%) ^b		
						[Pd]	T
1	PdCl_2	Cu(OAc)_2	—	CH_3CN	33		
2	PdCl_2	CuCl_2	—	CH_3CN	N.D.		
3	PdCl_2	DDQ	—	CH_3CN	N.D.		
4	PdCl_2	BQ	—	CH_3CN	N.D.		
5	PdCl_2	Cu(OAc)_2	—	DMSO	N.D.		
6	PdCl_2	Cu(OAc)_2	—	DMF	18		
7	PdCl_2	Cu(OAc)_2	—	toluene	12		
8	PdCl_2	Cu(OAc)_2	—	1,4-dioxane	21		
9	PdCl_2	Cu(OAc)_2	<i>t</i> -BuOLi	CH_3CN	44		
10	PdCl_2	Cu(OAc)_2	PivOH	CH_3CN	39		
11	PdCl_2	Cu(OAc)_2	HOAc	CH_3CN	N.D.		
12	PdCl_2	Cu(OAc)_2	Et_3N	CH_3CN	80 (76) ^c		
13	PdCl_2	Cu(OAc)_2	DBU	CH_3CN	N.D.		
14	PdCl_2	Cu(OAc)_2	pyridine	CH_3CN	N.D.		
15	PdCl_2	Cu(OAc)_2	DABCO	CH_3CN	72		
16	PdCl_2	Cu(OAc)_2	<i>N</i> -methylmorpholine	CH_3CN	N.D.		
17	PdCl_2	Cu(OAc)_2	Bu_3N	CH_3CN	69		
18	Pd(OAc)_2	Cu(OAc)_2	Et_3N	CH_3CN	67		
19	Pd(TFA)_2	Cu(OAc)_2	Et_3N	CH_3CN	44		
20 ^d	PdCl_2	Cu(OAc)_2	Et_3N	CH_3CN	42		

^aReaction conditions: **1a** (0.1 mmol), **2a** (0.15 mmol), catalyst (10 mol %), oxidant (3 equiv) and additive (2 equiv) in 1 mL of solvent under at 80 °C for 12 h. ^bDetermined by GC. ^cIsolated yield. ^dAt 50 °C.

3aj. In addition, disubstituted phenylboronic acid could be employed as substrate to give moderate yield of the corresponding product (3ak). Unfortunately, *ortho*-halogen phenylboronic acids gave no desired product in this transformation (3al).

In view of the aforementioned results, we turned our attention to the scope of substituted homoallylic amines (Table 3).

Table 3. Substrate Scope of N-Homoallyliamines^{a,b}



^aReaction conditions: 1a (0.1 mmol), 2 (0.15 mmol), PdCl₂ (10 mol %), Et₃N (2 equiv) and Cu(OAc)₂ (3 equiv) in 1 mL CH₃CN at 80 °C for 12 h.


^bIsolated yield. ^cThe reaction was stirred for 24 h. ^dThe reaction was stirred for 36 h. ^eThe reaction was stirred for 48 h.

Overall, the desired products were generated in moderate to good yields for various substituted homoallylic amines. When R¹ equaled to H, 67% yield of product 3ba was obtained. Functional groups such as OMe, F, Cl and Br on the aryl ring were also tolerated in this transformation and gave pyrrole derivatives in 59–79% yields (3ca–3fa). Yield remained good when R¹ switched from *para*-position to *meta*-position (3ga). However, when R¹ was *ortho*-substituent, only trace of desired product could be detected (3ha). For the component with disubstituents on the aryl ring, the reactions proceeded well to generate 3ia in 80% yield. To our delight, substrates bearing different R², including alkyl, alkyl ester, phenyl, naphthyl, all allowed the formation of corresponding products (3ja–3na). In addition, a slightly lower yield was observed when R³ was phenyl group (3oa). When 4-methyl-N-(4-methylpent-4-en-2-yl)aniline (1p) was used as the substrate, no reaction occurred. Only trace amount of product was obtained when N-phenyl

was changed to N-benzyl group (3qa), which suggested that N-phenyl was crucial to this transformation.

Both oxidative arylation and aminopalladation start with palladium(II) catalyst, which means they might be competitive in one process. To gain further insight into the mechanistic information, we carried out several experiments under the standard conditions. The transformation still proceeded well to construct pyrroles when we only used homoallylic amines as the substrates. As shown in Scheme 2, 4a and 4b were obtained

Scheme 2. Control Experiments



in 75 and 64% yields, respectively (eq 1). In addition, no desired product was afforded between 4a and phenylboronic acid under the standard conditions (eq 2). Then we shorten the time of the reaction between 1g and 2a from 36 to 12 h and successfully isolated intermediate 5 (eq 3), which indicated that the oxidative Heck reaction occurred first, followed by the intramolecular aminopalladation.


On the basis of the above information and previous reports,⁹ a putative reaction pathway for this transformation is shown in Scheme 3. Arylpalladium(II) species was first formed by transmetalation of arylboronic acid, followed by migratory insertion of the olefin and β -hydride elimination to produce intermediate B. Then, intramolecular aminopalladation gave palladium(II)-alkyl complex C, and subsequently a second β -hydride elimination generated intermediate 5. Finally, oxidative dehydrogenation afforded the desired product 3. The Pd(0) species obtained in two β -hydride elimination process was oxidized by Cu(OAc)₂ to regenerate the Pd(II) species.

In summary, we have elaborated the Pd(II)-catalyzed oxidative arylative cyclization of N-homoallylic amines. Four hydrogen atoms were removed to forge C–N and C–C bonds in this protocol via sequential unreactive alkene oxidative arylation and intramolecular aza-Wacker-type cyclization. The present reaction allowed simple conversion of accessible starting materials to various polysubstituted pyrroles.

EXPERIMENTAL SECTION

General Method. ¹H and ¹³C NMR spectra were recorded on a 400 MHz spectrometer using CDCl₃ as solvent and TMS as an internal standard. Mass spectra were obtained with gas chromatography mass spectrometer. IR spectra were obtained either as potassium bromide pellets or as liquid films between two potassium bromide pellets with a spectrometer. GC–MS was obtained using electron

Scheme 3. Proposed Mechanism



ionization. HRMS was obtained with a LCMS-IT-TOF mass spectrometer.

General Procedure for Synthesis of Homoallylic Amines 1a–1i.^{13a} Arylamine (1.2 mmol) and K₂CO₃ (2 mmol) were added to 3 mL of DMF. Allyl bromide (1 mmol) was slowly added to the mixture, which was stirred at 80 °C overnight. After that, water was added, and the mixture was extracted with ethyl acetate. The combined organic layer was dried over Na₂SO₄, filtered, concentrated and eventually purified by column chromatography on a silica gel to give 1a–1i with petroleum ether/ethyl acetate as the eluent.

General Procedure for Synthesis of Homoallylic Amines 1j, 1k, 1o, 1p.^{13b} A suspension of indium (2 mmol) and allyl bromide (3 mmol) in THF (2 mL) was stirred at room temperature under N₂ for 1 h. Then aniline (1 mmol) and ethyl vinyl ether (2 mmol) were added to the reaction mixture, which was stirred for another 2 h. The solution was quenched by saturated aqueous NH₄Cl (5 mL) and extracted with ethyl acetate. The organic layer was washed with water, dried over Na₂SO₄, filtered and concentrated. The residue was separated by column chromatography on a silica gel to afford the corresponding homoallylic amines with petroleum ether/ethyl acetate as the eluent.

General Procedure for Synthesis of Homoallylic Amines 1l–1n, 1q.^{13c} A suspension of allylmagnesium bromide (1.0 M in THF, 1.0 mL, 1.3 mmol) and ZnCl₂ (0.1 mmol) was stirred at room temperature under N₂ for 1 h. Then, imine (1 mmol) was added to the mixture, which was stirred at room temperature for 2 h. The solution was quenched by saturated aqueous NH₄Cl (5 mL) and extracted with ethyl acetate. The organic layer was washed with water, dried over Na₂SO₄, filtered and concentrated. The residue was further purified by column chromatography on a silica gel to give corresponding compounds with petroleum ether/ethyl acetate as the eluent.

General Procedure for Synthesis of Pyrrole Derivatives. Homoallylic amine (0.1 mmol), arylboronic acid (0.15 mmol), PdCl₂ (10 mol %), Cu(OAc)₂ (3 equiv) and Et₃N (2 equiv) were added to 1 mL of CH₃CN. The mixture was stirred under air at 80 °C for the desired reaction time. After that, water was added and extracted with ethyl acetate twice. The combined organic phase was dried over Na₂SO₄ and concentrated. The residue was eventually purified by flash column chromatography on a silica gel to afford the product with petroleum ether/ethyl acetate as the eluent.

N-(But-3-en-1-yl)-4-methylaniline (1a). ¹H NMR (400 MHz, CDCl₃) δ = 7.05 (d, J = 7.9 Hz, 2H), 6.60 (d, J = 7.9 Hz, 2H), 5.97–5.78 (m, 1H), 5.18 (t, J = 14.0 Hz, 2H), 3.84 (s, 1H), 3.22 (t, J = 6.6 Hz, 2H), 2.43 (dd, J = 13.4, 6.7 Hz, 2H), 2.30 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ = 146.1, 135.9, 129.8, 126.6, 117.0, 113.2, 43.3, 33.7, 20.4 ppm; MS (EI, 70 eV) m/z 91, 120, 261; HRMS (ESI) m/z calcd for C₁₁H₁₆N [M + H]⁺, 162.1277, found 162.1278; IR (KBr) 3407, 2919, 2861, 1616, 1519, 1479, 1323, 808 cm⁻¹.

N-(But-3-en-1-yl)aniline (1b). ¹H NMR (400 MHz, CDCl₃) δ = 7.22 (t, J = 7.2 Hz, 2H), 6.75 (t, J = 7.3 Hz, 1H), 6.66 (d, J = 7.8 Hz, 2H), 5.88 (td, J = 16.5, 7.3 Hz, 1H), 5.18 (t, J = 14.3 Hz, 2H), 3.70 (s, 1H), 3.23 (t, J = 6.6 Hz, 2H), 2.43 (q, J = 6.5 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ = 148.3, 135.8, 129.2, 117.4, 117.1, 112.9, 42.9, 33.7 ppm; MS (EI, 70 eV) m/z 77, 106, 147; HRMS (ESI) m/z calcd for

C₁₀H₁₄N [M + H]⁺, 148.1121, found 148.1121; IR (KBr) 3411, 3079, 2926, 2833, 1732, 1600, 1510, 1434, 1321, 918 cm⁻¹.

N-(But-3-en-1-yl)-4-methoxyaniline (1c). ¹H NMR (400 MHz, CDCl₃) δ = 6.77 (d, J = 7.9 Hz, 2H), 6.58 (d, J = 7.7 Hz, 2H), 5.99–5.66 (m, 1H), 5.11 (t, J = 13.6 Hz, 2H), 3.71 (d, J = 15.8 Hz, 3H), 3.15 (dd, J = 19.2, 12.6 Hz, 2H), 2.36 (q, J = 6.5 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ = 152.2, 142.7, 135.9, 117.0, 114.9, 114.3, 55.8, 43.9, 33.7 ppm; MS (EI, 70 eV) m/z 108, 121, 136, 177; HRMS (ESI) m/z calcd for C₁₁H₁₆NO [M + H]⁺, 178.1226, found 178.1226; IR (KBr) 3392, 2929, 2830, 1513, 1468, 1237, 819 cm⁻¹.

N-(But-3-en-1-yl)-4-fluoroaniline (1d). ¹H NMR (400 MHz, CDCl₃) δ = 6.93 (t, J = 8.0 Hz, 2H), 6.58 (dd, J = 6.9, 4.4 Hz, 2H), 5.97–5.78 (m, 1H), 5.18 (t, J = 12.4 Hz, 2H), 3.49 (s, 1H), 3.18 (t, J = 6.5 Hz, 2H), 2.41 (q, J = 6.5 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ = 155.9 (d, J = 233.0 Hz), 144.7, 135.7, 117.2, 115.6 (d, J = 18.0 Hz), 113.73 (d, J = 7.4 Hz, 1H), 43.5, 33.6 ppm; MS (EI, 70 eV) m/z 75, 95, 124, 165; HRMS (ESI) m/z calcd for C₁₀H₁₃FN [M + H]⁺, 166.1027, found 166.1025; IR (KBr) 3409, 3079, 2928, 2852, 1612, 1514, 1317, 1219, 820 cm⁻¹.

N-(But-3-en-1-yl)-4-chloroaniline (1e). ¹H NMR (400 MHz, CDCl₃) δ = 7.15 (d, J = 8.2 Hz, 2H), 6.56 (d, J = 7.8 Hz, 2H), 5.85 (td, J = 16.8, 7.1 Hz, 1H), 5.24–5.07 (m, 2H), 3.69 (s, 1H), 3.18 (t, J = 6.5 Hz, 2H), 2.41 (q, J = 6.5 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ = 146.8, 135.5, 129.0, 121.9, 117.3, 113.9, 42.9, 33.5 ppm; MS (EI, 70 eV) m/z 75, 95, 105, 140, 181; HRMS (ESI) m/z calcd for C₁₀H₁₃ClN [M + H]⁺, 182.0731, found 182.0729; IR (KBr) 3412, 3078, 2925, 2851, 1601, 1503, 1318, 815 cm⁻¹.

4-Bromo-N-(but-3-en-1-yl)aniline (1f). ¹H NMR (400 MHz, CDCl₃) δ = 7.28 (d, J = 7.7 Hz, 2H), 6.51 (d, J = 7.8 Hz, 2H), 5.85 (td, J = 16.8, 7.2 Hz, 1H), 5.26–5.09 (m, 2H), 3.69 (s, 1H), 3.18 (t, J = 6.5 Hz, 2H), 2.41 (q, J = 6.6 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ = 147.3, 135.5, 131.9, 117.3, 114.4, 108.9, 42.8, 33.5 ppm; MS (EI, 70 eV) m/z 91, 118, 132, 160, 192, 233; HRMS (ESI) m/z calcd for C₁₀H₁₃BrN [M + H]⁺, 226.0226, found 226.0226; IR (KBr) 3411, 3076, 2925, 2849, 1595, 1502, 1320, 812 cm⁻¹.

N-(But-3-en-1-yl)-3-methylaniline (1g). ¹H NMR (400 MHz, CDCl₃) δ = 7.15 (t, J = 7.3 Hz, 1H), 6.62 (d, J = 7.0 Hz, 1H), 6.51 (d, J = 7.7 Hz, 2H), 5.91 (td, J = 16.2, 7.3 Hz, 1H), 5.21 (t, J = 14.5 Hz, 2H), 3.61 (s, 1H), 3.25 (t, J = 6.6 Hz, 2H), 2.44 (dd, J = 13.6, 7.7 Hz, 2H), 2.35 (d, J = 14.7 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ = 148.4, 139.0, 135.9, 129.2, 118.4, 117.0, 113.8, 110.1, 42.9, 33.7, 21.7 ppm; MS (EI, 70 eV) m/z 91, 120, 261; HRMS (ESI) m/z calcd for C₁₁H₁₆N [M + H]⁺, 162.1277, found 162.1278; IR (KBr) 3410, 3043, 2919, 2847, 1609, 1514, 1424, 1328, 769 cm⁻¹.

N-(But-3-en-1-yl)-2-methylaniline (1h). ¹H NMR (400 MHz, CDCl₃) δ = 7.23 (t, J = 7.6 Hz, 1H), 7.14 (d, J = 7.2 Hz, 1H), 6.74 (dd, J = 19.0, 7.7 Hz, 2H), 5.95 (td, J = 16.8, 7.1 Hz, 1H), 5.24 (t, J = 14.9 Hz, 2H), 3.61 (s, 1H), 3.32 (t, J = 6.6 Hz, 2H), 2.53 (q, J = 6.5 Hz, 2H), 2.21 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ = 146.2, 136.0, 130.1, 127.2, 122.0, 117.1, 116.9, 109.9, 42.7, 33.7, 17.39 ppm; MS (EI, 70 eV) m/z 91, 120, 261; HRMS (ESI) m/z calcd for C₁₁H₁₆N [M + H]⁺, 162.1277, found 162.1278; IR (KBr) 3421, 3076, 2920, 2851, 1607, 1512, 1443, 1316, 745 cm⁻¹.

N-(But-3-en-1-yl)-3,5-dimethylaniline (1i). ^1H NMR (400 MHz, CDCl_3) δ = 6.44 (s, 1H), 6.33 (s, 2H), 5.89 (tt, J = 8.8, 7.1 Hz, 1H), 5.19 (t, J = 14.9 Hz, 2H), 3.56 (s, 1H), 3.23 (t, J = 6.4 Hz, 2H), 2.44 (dd, J = 13.0, 6.4 Hz, 2H), 2.33 (d, J = 14.9 Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ = 148.4, 138.9, 135.9, 119.5, 117.0, 110.9, 42.9, 33.7, 21.5 ppm; MS (EI, 70 eV) m/z 77, 134, 175; HRMS (ESI) m/z calcd for $\text{C}_{12}\text{H}_{18}\text{N} [\text{M} + \text{H}]^+$, 176.1434, found 176.1434; IR (KBr) 3408, 2916, 2853, 1603, 1513, 1472, 1302, 1178, 821 cm^{-1} .

4-Methyl-N-(pent-4-en-2-yl)aniline (1j). ^1H NMR (400 MHz, CDCl_3) δ = 6.97 (d, J = 7.9 Hz, 2H), 6.51 (d, J = 7.9 Hz, 2H), 5.82 (dt, J = 16.6, 7.3 Hz, 1H), 5.15–4.97 (m, 2H), 3.51 (dd, J = 12.3, 6.1 Hz, 1H), 2.38–2.29 (m, 1H), 2.28–2.13 (m, 4H), 1.17 (d, J = 6.3 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ = 145.1, 135.1, 129.8, 126.4, 117.5, 113.7, 48.4, 40.9, 20.5, 20.4 ppm; MS (EI, 70 eV) m/z 91, 119, 134, 175; HRMS (ESI) m/z calcd for $\text{C}_{12}\text{H}_{18}\text{N} [\text{M} + \text{H}]^+$, 176.1434, found 176.1434; IR (KBr) 3404, 2970, 2922, 2865, 1617, 1518, 1302, 807 cm^{-1} .

Methyl 3-(*p*-tolylamino)hex-5-enoate (1k). ^1H NMR (400 MHz, CDCl_3) δ = 6.99 (d, J = 7.6 Hz, 2H), 6.57 (d, J = 7.6 Hz, 2H), 5.81 (dt, J = 16.0, 7.5 Hz, 1H), 5.11 (d, J = 13.0 Hz, 2H), 3.92–3.83 (m, 1H), 3.66 (s, 3H), 2.54 (ddd, J = 32.9, 15.3, 6.1 Hz, 2H), 2.44–2.31 (m, 2H), 2.23 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ = 172.3, 134.1, 129.9, 127.2, 118.3, 114.1, 51.6, 50.4, 38.5, 38.4, 20.4 ppm; MS (EI, 70 eV) m/z 91, 118, 160, 192, 233; HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{20}\text{NO}_2 [\text{M} + \text{H}]^+$, 234.1489, found 234.1491; IR (KBr) 3414, 3018, 2918, 2862, 1616, 1518, 1484, 1300, 1089, 919, 809 cm^{-1} .

N-(1-(4-Chlorophenyl)but-3-en-1-yl)-4-methylaniline (1l). ^1H NMR (400 MHz, CDCl_3) δ = 7.40 (d, J = 2.2 Hz, 4H), 7.03 (d, J = 4.7 Hz, 2H), 6.63–6.49 (m, 2H), 5.96–5.69 (m, 1H), 5.38–5.13 (m, 2H), 4.55–4.33 (m, 1H), 4.11 (s, 1H), 2.81–2.45 (m, 2H), 2.32 (d, J = 2.6 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ = 144.9, 142.5, 134.4, 132.6, 129.7, 128.8, 127.9, 126.9, 118.7, 113.8, 57.0, 43.3, 20.5 ppm; MS (EI, 70 eV) m/z 91, 118, 230, 271; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{19}\text{ClN} [\text{M} + \text{H}]^+$, 272.1201, found 272.1200; IR (KBr) 3403, 2919, 2862, 1735, 1617, 1519, 1437, 1297, 1202, 810 cm^{-1} .

4-Methyl-N-(*p*-phenylbut-3-en-1-yl)aniline (1m). ^1H NMR (400 MHz, CDCl_3) δ = 7.57–7.31 (m, 5H), 7.03 (s, 2H), 6.57 (s, 2H), 6.00–5.83 (m, 1H), 5.29 (t, J = 14.2 Hz, 2H), 4.55–4.40 (m, 1H), 3.99 (s, 1H), 2.67 (dd, J = 38.2, 5.1 Hz, 2H), 2.32 (d, J = 3.0 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ = 145.2, 143.9, 134.9, 129.7, 128.7, 127.0, 126.6, 126.4, 118.3, 113.7, 57.5, 43.4, 20.5 ppm; MS (EI, 70 eV) m/z 90, 118, 196, 237; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{20}\text{N} [\text{M} + \text{H}]^+$, 238.1590, found 238.1592; IR (KBr) 3413, 3024, 2919, 2860, 1616, 1518, 1301, 807 cm^{-1} .

4-Methyl-N-(1-naphthalen-1-yl)but-3-en-1-yl)aniline (1n). ^1H NMR (400 MHz, CDCl_3) δ = 8.51 (d, J = 5.1 Hz, 1H), 8.25–8.16 (m, 1H), 8.01 (dd, J = 16.3, 7.1 Hz, 2H), 7.94–7.75 (m, 2H), 7.69 (dd, J = 8.6, 6.3 Hz, 1H), 7.18 (d, J = 4.1 Hz, 2H), 6.74 (s, 2H), 6.29–6.00 (m, 1H), 5.53 (dd, J = 16.8, 8.9 Hz, 2H), 4.64–4.33 (m, 1H), 3.14 (d, J = 13.4 Hz, 1H), 2.86 (d, J = 7.2 Hz, 1H), 2.50 (d, J = 2.4 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ = 145.3, 138.7, 135.3, 134.6, 131.1, 129.9, 129.6, 127.8, 126.7, 126.4, 126.1, 125.7, 123.6, 122.7, 118.5, 113.9, 53.6, 41.9, 20.7 ppm; MS (EI, 70 eV) m/z 91, 118, 246, 287; HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{22}\text{N} [\text{M} + \text{H}]^+$, 288.1747, found 288.1745; IR (KBr) 3416, 3070, 2916, 2861, 1616, 1517, 1302, 1261, 918, 808 cm^{-1} .

4-Methyl-N-(3-phenylpent-4-en-2-yl)aniline (1o). According to ref 23, **1o** has enantiomers, dr = 67:33. ^1H NMR (400 MHz, CDCl_3) δ = 7.27–7.06 (m, 5H), 6.90 (s, 2H), 6.45 (d, J = 6.1 Hz, 2H), 6.18–5.99 (m, 1H), 5.18–4.99 (m, 2H), 3.71–3.66 (m, 1H), 3.49–3.47 (m, 1H), 2.15 (d, 3H), 1.03 (d, 3H), 0.93 (d, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ = 145.0, 144.9, 141.8, 141.0, 139.4, 136.9, 130.0, 129.9, 128.6, 128.4, 128.1, 126.6, 126.5, 117.9, 116.6, 114.2, 113.8, 54.9, 54.4, 52.8, 52.7, 20.5, 18.3, 17.2 ppm; MS (EI, 70 eV) m/z 91, 134, 251; HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{22}\text{N} [\text{M} + \text{H}]^+$, 252.1747, found 252.1750; IR (KBr) 3405, 3025, 2971, 2921, 2865, 1616, 1517, 1450, 1299, 807, 701 cm^{-1} .

4-Methyl-N-(4-methylpent-4-en-2-yl)aniline (1p). ^1H NMR (400 MHz, CDCl_3) δ = 7.04 (d, J = 7.9 Hz, 2H), 6.59 (d, J = 7.9 Hz, 2H), 4.85 (d, J = 24.7 Hz, 2H), 3.63 (dd, J = 12.9, 6.4 Hz, 1H), 3.22 (s, 1H),

2.39 (dd, J = 13.8, 6.7 Hz, 1H), 2.29 (s, 3H), 2.16 (dd, J = 13.9, 7.1 Hz, 1H), 1.80 (s, 3H), 1.24 (d, J = 6.2 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ = 145.3, 143.1, 129.8, 126.4, 113.5, 112.9, 46.8, 45.6, 22.4, 20.9, 20.4 ppm; MS (EI, 70 eV) m/z 91, 119, 134, 189; HRMS (ESI) m/z calcd for $\text{C}_{12}\text{H}_{18}\text{N} [\text{M} + \text{H}]^+$, 190.1590, found 190.1591; IR (KBr) 3403, 2968, 2923, 2862, 1650, 1518, 1451, 807 cm^{-1} .

N-Benzyl-1-phenylbut-3-en-1-amine (1q). ^1H NMR (400 MHz, CDCl_3) δ = 7.43–7.18 (m, 10H), 5.70 (td, J = 16.9, 8.1 Hz, 1H), 5.04 (t, J = 13.9 Hz, 2H), 3.68 (dd, J = 13.4, 6.2 Hz, 2H), 3.52 (d, J = 13.3 Hz, 1H), 2.40 (d, J = 8.7 Hz, 2H), 1.93 (s, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ = 143.8, 140.6, 135.5, 128.5, 128.4, 128.2, 127.4, 127.1, 126.9, 117.6, 61.7, 51.5, 43.1 ppm; MS (EI, 70 eV) m/z 91, 196, 236; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{20}\text{N} [\text{M} + \text{H}]^+$, 238.1590, found 238.1595; IR (KBr) 3324, 3080, 3062, 2927, 2836, 1603, 1493, 1455, 915, 699 cm^{-1} .

2-Phenyl-1-(*p*-tolyl)-1*H*-pyrrole (3aa). ¹⁴ (Yellow oil). Yield (17.5 mg, 76%). ^1H NMR (400 MHz, CDCl_3) δ = 7.17 (ddd, J = 19.2, 12.9, 8.1 Hz, 7H), 7.07 (d, J = 7.7 Hz, 2H), 6.92 (s, 1H), 6.44 (s, 1H), 6.36 (s, 1H), 2.36 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ = 138.1, 136.4, 133.8, 133.1, 129.6, 128.3, 128.0, 126.2, 125.6, 124.4, 110.4, 109.0, 21.0 ppm; MS (EI, 70 eV) m/z 115, 129, 233; IR (KBr) 3266, 3073, 2928, 2867, 1598, 1513, 1424, 1325, 1158, 1090 cm^{-1} .

2-(4-Ethylphenyl)-1-(*p*-tolyl)-1*H*-pyrrole (3ab). (Yellow oil). Yield (18.3 mg, 70%). ^1H NMR (400 MHz, CDCl_3) δ = 7.20–7.01 (m, 8H), 6.91 (s, 1H), 6.41 (s, 1H), 6.36 (s, 1H), 2.62 (q, J = 7.6 Hz, 2H), 2.37 (s, 3H), 1.23 (t, J = 7.6 Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 142.2, 138.2, 136.3, 133.9, 130.5, 129.6, 128.2, 127.5, 125.6, 124.1, 110.1, 108.9, 28.5, 21.0, 15.3 ppm; MS (EI, 70 eV) m/z 91, 115, 128, 246, 261; HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{20}\text{N} [\text{M} + \text{H}]^+$, 262.1588, found 262.1590; IR (KBr) 3309, 3112, 2965, 1705, 1575, 1513, 1460, 1266, 754 cm^{-1} .

2-[1,1'-Biphenyl]-4-yl-1-(*p*-tolyl)-1*H*-pyrrole (3ac). (White solid). Yield (23.2 mg, 75%). mp 127–128 $^{\circ}\text{C}$. ^1H NMR (400 MHz, CDCl_3) δ = 7.58 (d, J = 7.7 Hz, 2H), 7.48–7.39 (m, 4H), 7.32 (t, J = 7.3 Hz, 1H), 7.21 (d, J = 7.8 Hz, 2H), 7.13 (q, J = 8.1 Hz, 4H), 6.94 (s, 1H), 6.49 (s, 1H), 6.38 (s, 1H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 140.7, 138.7, 138.1, 136.5, 133.4, 132.1, 129.7, 128.7, 128.5, 127.0, 126.7, 125.6, 124.7, 110.6, 109.1, 21.0 ppm; MS (EI, 70 eV) m/z 91, 115, 129, 191, 309; HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{20}\text{N} [\text{M} + \text{H}]^+$, 310.1588, found 310.1590; IR (KBr) 3302, 3114, 2923, 1712, 1579, 1514, 1266, 755 cm^{-1} .

2-(4-Fluorophenyl)-1-(*p*-tolyl)-1*H*-pyrrole (3ad). (Yellow oil). Yield (19.8 mg, 79%). ^1H NMR (400 MHz, CDCl_3) δ 7.17–7.07 (m, 4H), 7.04 (d, J = 8.1 Hz, 2H), 6.90 (t, J = 8.6 Hz, 3H), 6.39–6.38 (m, 1H), 6.34 (t, J = 2.9 Hz, 1H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 160.5 (d, J = 244 Hz), 136.8, 135.5, 131.8, 128.86 (d, J = 7.9 Hz), 128.6, 128.2 (d, J = 4 Hz), 124.5, 123.3, 113.9 (d, J = 22 Hz), 109.2, 107.9, 20.0 ppm; MS (EI, 70 eV) m/z 91, 115, 133, 251; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{15}\text{FN} [\text{M} + \text{H}]^+$, 252.1177, found 252.1183; IR (KBr) 2200, 2110, 2965, 1720, 1551, 1510, 1462, 1266, 754 cm^{-1} .

2-(4-Chlorophenyl)-1-(*p*-tolyl)-1*H*-pyrrole (3ae). (White solid). Yield (22.2 mg, 83%). mp 88–89 $^{\circ}\text{C}$. ^1H NMR (400 MHz, CDCl_3) δ = 7.15 (dd, J = 14.0, 8.2 Hz, 4H), 7.05 (t, J = 6.9 Hz, 4H), 6.91 (s, 1H), 6.42 (s, 1H), 6.35 (s, 1H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 137.8, 136.7, 132.6, 131.6, 129.7, 129.4, 128.2, 125.6, 124.8, 110.7, 109.1, 21.0 ppm; MS (EI, 70 eV) m/z 115, 129, 311; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{15}\text{ClN} [\text{M} + \text{H}]^+$, 268.0881, found 268.0888; IR (KBr) 3299, 3113, 1711, 1572, 1514, 826, 753 cm^{-1} .

2-(4-Bromophenyl)-1-(*p*-tolyl)-1*H*-pyrrole (3af). (White solid). Yield (26.1 mg, 84%). mp 100–101 $^{\circ}\text{C}$. ^1H NMR (400 MHz, CDCl_3) δ = 7.32 (d, J = 7.9 Hz, 2H), 7.14 (d, J = 7.8 Hz, 2H), 7.02 (dd, J = 18.4, 7.9 Hz, 4H), 6.92 (s, 1H), 6.43 (m, 1H), 6.35 (s, 1H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 137.8, 136.7, 132.6, 132.0, 131.2, 129.8, 129.7, 125.6, 124.9, 120.2, 110.7, 109.2, 21.0 ppm; MS (EI, 70 eV) m/z 115, 129, 311; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{15}\text{BrN} [\text{M} + \text{H}]^+$, 312.0377, found 312.0382; IR (KBr) 3307, 3038, 2921, 1707, 1575, 1514, 1457, 1266, 823, 753 cm^{-1} .

Methyl 4-(1-(*p*-tolyl)-1*H*-pyrrol-2-yl)benzoate (3ag). (White solid). Yield (17.4 mg, 60%). mp 86–87 $^{\circ}\text{C}$. ^1H NMR (400 MHz, CDCl_3) δ = 7.86 (d, J = 7.4 Hz, 2H), 7.16 (dd, J = 18.1, 7.6 Hz, 4H),

7.05 (d, $J = 7.6$ Hz, 2H), 6.94 (s, 1H), 6.53 (s, 1H), 6.36 (s, 1H), 3.88 (s, 3H), 2.36 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ = 167.0, 137.8, 137.5, 136.9, 132.7, 129.8, 129.4, 127.6, 127.4, 125.8, 125.6, 111.8, 109.4, 52.0, 21.0 ppm; MS (EI, 70 eV) m/z 91, 115, 130, 232, 260, 291; HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{18}\text{NO}_2$ [$\text{M} + \text{H}]^+$, 292.1337, found 292.1332; IR (KBr) 3300, 3114, 1719, 1600, 1568, 1515, 1277 cm^{-1} .

2-(3-Chlorophenyl)-1-(*p*-tolyl)-1*H*-pyrrole (3ah). (Yellow oil). Yield (21.6 mg, 81%). ^1H NMR (400 MHz, CDCl_3) δ = 7.20 (s, 1H), 7.04–7.15 (m, 6H), 6.92 (s, 2H), 6.44 (s, 1H), 6.34 (s, 1H), 2.37 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 137.7, 136.8, 134.9, 133.9, 132.3, 129.7, 129.2, 128.0, 126.3, 126.1, 125.5, 125.1, 111.1, 109.2, 21.0 ppm; MS (EI, 70 eV) m/z 115, 129, 267; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{15}\text{ClN}$ [$\text{M} + \text{H}]^+$, 268.0889, found 268.0888; IR (KBr) 3113, 1713, 1565, 1516, 1266, 751 cm^{-1} .

2-(*m*-Tolyl)-1-(*p*-tolyl)-1*H*-pyrrole (3ai). (Yellow oil). Yield (19.0 mg, 77%). ^1H NMR (400 MHz, CDCl_3) δ = 7.15–7.04 (m, 6H), 6.98 (d, $J = 7.4$ Hz, 1H), 6.91 (s, 1H), 6.87 (d, $J = 7.6$ Hz, 1H), 6.42 (s, 1H), 6.35 (t, $J = 2.7$ Hz, 1H), 2.36 (s, 3H), 2.27 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) = 138.2, 137.6, 136.3, 133.9, 133.0, 129.5, 129.0, 127.8, 127.0, 125.5, 125.4, 124.3, 110.3, 108.9, 21.4, 21.0 ppm; MS (EI, 70 eV) m/z 91, 115, 129, 247; HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{18}\text{N}$ [$\text{M} + \text{H}]^+$, 248.1429, found 248.1434; IR (KBr) 3035, 2922, 1700, 1599, 1514, 1466, 1334, 822, 775, 709 cm^{-1} .

2-(Naphthalen-2-yl)-1-(*p*-tolyl)-1*H*-pyrrole (3aj). (Yellow oil). Yield (24.9 mg, 88%). ^1H NMR (400 MHz, CDCl_3) δ = 7.79–7.75 (m, 1H), 7.72–7.63 (m, 3H), 7.45–7.39 (m, 2H), 7.23 (d, $J = 8.5$ Hz, 1H), 7.11 (s, 4H), 6.98 (s, 1H), 6.57–6.56 (m, 1H), 6.41 (s, 1H), 2.36 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 138.1, 136.5, 133.8, 133.4, 131.9, 130.7, 129.7, 127.9, 127.6, 127.4, 126.8, 126.6, 126.0, 125.6, 125.5, 124.7, 110.9, 109.2, 21.0 ppm; MS (EI, 70 eV) m/z 91, 115, 133, 165, 283; HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{18}\text{N}$ [$\text{M} + \text{H}]^+$, 284.1033, found 284.1034; IR (KBr) 3052, 2928, 1711, 1571, 1513, 1457, 1334, 820, 747, 714 cm^{-1} .

2-(3-Chloro-4-methylphenyl)-1-(*p*-tolyl)-1*H*-pyrrole (3ak). (Yellow oil). Yield (19.7 mg, 70%). ^1H NMR (400 MHz, CDCl_3) δ = 7.20 (s, 1H), 7.13 (d, $J = 8.0$ Hz, 2H), 7.04 (d, $J = 7.8$ Hz, 2H), 7.01 (d, $J = 7.9$ Hz, 1H), 6.89 (s, 1H), 6.81 (d, $J = 7.9$ Hz, 1H), 6.41–6.40 (m, 1H), 6.33 (s, 1H), 2.36 (s, 3H), 2.31 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 137.8, 136.7, 134.0, 133.7, 132.3, 130.4, 129.7, 128.5, 126.4, 125.6, 124.7, 110.6, 110.1, 109.1, 21.0, 19.7 ppm; MS (EI, 70 eV) m/z 91, 115, 129, 281; HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{17}\text{ClN}$ [$\text{M} + \text{H}]^+$, 282.1044, found 282.1044; IR (KBr) 3109, 2926, 1713, 1561, 1513, 1460, 1335, 822 cm^{-1} .

1,2-Diphenyl-1*H*-pyrrole (3ba).¹⁵ (White solid). Yield (14.7 mg, 67%). mp 88–90 °C. ^1H NMR (400 MHz, CDCl_3) δ = 7.30 (m, 3H), 7.17 (td, $J = 14.5, 7.2$ Hz, 7H), 6.94 (s, 1H), 6.44 (s, 1H), 6.36 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ = 140.6, 133.8, 133.0, 129.0, 128.3, 128.1, 126.6, 126.3, 125.8, 124.4, 110.7, 109.2 ppm; MS (EI, 70 eV) m/z 77, 108, 115, 219; IR (KBr) 3055, 2924, 1715, 1591, 1396, 1461, 1329, 759, 697 cm^{-1} .

1-(4-Methoxyphenyl)-2-phenyl-1*H*-pyrrole (3ca).¹⁶ (Yellow oil). Yield (19.7 mg, 79%). ^1H NMR (400 MHz, CDCl_3) δ = 7.16 (ddd, $J = 24.1, 15.4, 7.7$ Hz, 7H), 6.89 (s, 1H), 6.85 (d, $J = 8.6$ Hz, 2H), 6.43 (s, 1H), 6.34 (t, $J = 2.6$ Hz, 1H), 3.81 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 158.2, 133.9, 133.8, 133.1, 128.2, 128.0, 126.9, 126.1, 124.5, 114.1, 110.1, 108.8, 55.4 ppm; MS (EI, 70 eV) m/z 77, 115, 234, 249; IR (KBr) 3054, 2923, 2845, 1712, 1595, 1511, 1462, 1248, 1034, 755 cm^{-1} .

1-(4-Fluorophenyl)-2-phenyl-1*H*-pyrrole (3da). (Yellow oil). Yield (14.0 mg, 60%). ^1H NMR (400 MHz, CDCl_3) δ = 7.20–7.00 (m, 6H), 6.93 (t, $J = 8.5$ Hz, 2H), 6.82 (s, 1H), 6.35 (s, 1H), 6.28 (t, $J = 2.7$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ = 160.1 (d, $J = 245$ Hz), 135.6 (d, $J = 3$ Hz), 132.9, 131.7, 127.2 (d, $J = 19$ Hz), 126.3 (d, $J = 8.4$ Hz), 125.3, 123.3, 114.9, 114.7, 109.6, 108.3 ppm; MS (EI, 70 eV) m/z 95, 115, 133, 237; HRMS (ESI) m/z calcd for $\text{C}_{16}\text{H}_{13}\text{FN}$ [$\text{M} + \text{H}]^+$, 238.1028, found 238.1027; IR (KBr) 3067, 2926, 1709, 1591, 1509, 1466, 1224, 838, 756 cm^{-1} .

1-(4-Chlorophenyl)-2-phenyl-1*H*-pyrrole (3ea).¹⁷ (Yellow oil). Yield (15.7 mg, 62%). ^1H NMR (400 MHz, CDCl_3) δ = 7.29–7.20 (m, 5H), 7.10 (dd, $J = 12.2, 8.2$ Hz, 4H), 6.90 (s, 1H), 6.42 (s, 1H), 6.36 ((t, $J = 3.1$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ = 139.1, 133.8, 132.6, 132.2, 129.1, 128.3, 128.2, 126.8, 126.5, 124.2, 111.0, 109.6 ppm; MS (EI, 70 eV) m/z 95, 108, 115, 217, 253; IR (KBr) 3110, 1709, 1580, 1495, 1334 cm^{-1} .

1-(4-Bromophenyl)-2-phenyl-1*H*-pyrrole (3fa).¹⁸ (Yellow oil). Yield (17.5 mg, 59%). ^1H NMR (400 MHz, CDCl_3) δ = 7.43 (d, $J = 8.2$ Hz, 2H), 7.21 (dd, $J = 12.5, 7.1$ Hz, 3H), 7.12 (d, $J = 7.6$ Hz, 2H), 7.03 (d, $J = 8.2$ Hz, 2H), 6.90 (s, 1H), 6.42 (s, 1H), 6.36 (t, $J = 2.7$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ = 139.6, 133.8, 132.7, 132.1, 128.3, 128.2, 127.1, 126.5, 124.1, 120.1, 111.1, 109.7 ppm; MS (EI, 70 eV) m/z 115, 143, 224, 299; IR (KBr) 3075, 2924, 1709, 1582, 1491, 1334, 755 cm^{-1} .

2-Phenyl-1-(*m*-tolyl)-1*H*-pyrrole (3ga). (Yellow oil). Yield (17.9 mg, 77%). ^1H NMR (400 MHz, CDCl_3) δ = 7.24–7.12 (m, 6H), 7.08 (d, $J = 7.6$ Hz, 1H), 7.04 (s, 1H), 6.93 (d, $J = 7.0$ Hz, 2H), 6.44 (s, 1H), 6.36 ((t, $J = 3.0$ Hz, 1H), 2.32 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 140.5, 139.0, 133.8, 133.1, 128.7, 128.2, 128.0, 127.4, 126.3, 126.2, 124.4, 123.0, 110.5, 109.1, 21.3 ppm; MS (EI, 70 eV) m/z 115, 129, 233; HRMS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{16}\text{N}$ [$\text{M} + \text{H}]^+$, 234.1276, found 234.1277; IR (KBr) 3106, 1710, 1588, 1493, 1336, 755, 701 cm^{-1} .

2-(3,5-Dimethylphenyl)-2-phenyl-1*H*-pyrrole (3ia). (Yellow oil). Yield (19.8 mg, 80%). ^1H NMR (400 MHz, CDCl_3) δ = 7.22–7.12 (m, 5H), 6.93–6.86 (m, 2H), 6.81–6.74 (m, 2H), 6.42 (m, 1H), 6.33 (s, 1H), 2.24 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ = 140.4, 138.6, 133.7, 133.1, 128.3, 128.1, 127.9, 126.1, 124.4, 123.5, 110.4, 108.9, 21.2 ppm; MS (EI, 70 eV) m/z 77, 115, 129, 247; HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{18}\text{N}$ [$\text{M} + \text{H}]^+$, 248.1435, found 248.1434; IR (KBr) 3108, 1712, 1598, 1475, 1346, 756 cm^{-1} .

2-Methyl-5-phenyl-1-(*p*-tolyl)-1*H*-pyrrole (3ja).¹⁹ (Yellow oil). Yield (20.0 mg, 81%). ^1H NMR (400 MHz, CDCl_3) δ = 7.29 (s, 1H), 7.17 (dd, $J = 11.2, 7.4$ Hz, 4H), 7.09 (dd, $J = 13.9, 7.5$ Hz, 5H), 6.38 (d, $J = 3.1$ Hz, 1H), 6.12 (d, $J = 2.7$ Hz, 1H), 2.41 (s, 3H), 2.16 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 137.2, 136.8, 134.2, 133.7, 131.8, 129.6, 128.2, 127.9, 127.8, 125.6, 108.5, 107.3, 21.1, 13.3 ppm; MS (EI, 70 eV) m/z 91, 115, 129, 191, 247; IR (KBr) 3035, 2924, 1714, 1593, 1513, 1450, 1396, 754 cm^{-1} .

Methyl 2-(5-phenyl-1-(*p*-tolyl)-1*H*-pyrrol-2-yl)acetate (3ka). (Yellow oil). Yield (18.3 mg, 60%). ^1H NMR (400 MHz, CDCl_3) δ = 7.06 (t, $J = 6.7$ Hz, 4H), 6.99 (dd, $J = 13.8, 7.7$ Hz, 5H), 6.32 (d, $J = 2.8$ Hz, 1H), 6.19 (d, $J = 2.8$ Hz, 1H), 3.51 (s, 3H), 3.46 (s, 2H), 2.29 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 171.1, 137.8, 136.0, 135.2, 133.3, 129.7, 128.5, 128.0, 127.9, 127.8, 125.9, 109.2, 108.9, 52.0, 33.1, 21.1 ppm; MS (EI, 70 eV) m/z 115, 230, 246, 305; HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{20}\text{NO}_2$ [$\text{M} + \text{H}]^+$, 306.1495, found 306.1489; IR (KBr) 3069, 2923, 1738, 1572, 1513, 1447 cm^{-1} .

2-(4-Chlorophenyl)-5-phenyl-1-(*p*-tolyl)-1*H*-pyrrole (3la). (White solid). Yield (25.7 mg, 75%). mp 199–200 °C. ^1H NMR (400 MHz, CDCl_3) δ = 7.15 (dd, $J = 12.0, 8.1$ Hz, 5H), 7.09–7.01 (m, 4H), 6.98 (d, $J = 8.3$ Hz, 2H), 6.89 (d, $J = 7.9$ Hz, 2H), 6.45 (s, 2H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 137.3, 136.2, 136.1, 134.5, 133.2, 132.0, 131.9, 129.8, 129.6, 128.7, 128.5, 128.1, 127.9, 126.3, 110.0, 109.9, 21.1 ppm; MS (EI, 70 eV) m/z 91, 145, 191, 205, 343; HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{19}\text{ClN}$ [$\text{M} + \text{H}]^+$, 344.1203, found 344.1201; IR (KBr) 3115, 1712, 1567, 1515, 1482, 826, 754 cm^{-1} .

2,5-Diphenyl-1-(*p*-tolyl)-1*H*-pyrrole (3ma).²⁰ (White solid). Yield (24.1 mg, 78%). mp 193–194 °C. ^1H NMR (400 MHz, CDCl_3) δ = 7.12–7.04 (m, 6H), 7.00 (d, $J = 7.3$ Hz, 4H), 6.95 (d, $J = 7.7$ Hz, 2H), 6.83 (d, $J = 7.7$ Hz, 2H), 6.39 (s, 2H), 2.24 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 137.0, 136.4, 135.9, 133.4, 129.4, 128.7, 128.6, 127.8, 126.1, 109.8, 21.1 ppm; MS (EI, 70 eV) m/z 91, 139, 191, 309; IR (KBr) 2991, 2924, 1764, 1600, 1513, 1454, 1381, 1242, 1056, 753 cm^{-1} .

2-(Naphthalen-1-yl)-5-phenyl-1-(*p*-tolyl)-1*H*-pyrrole (3na). (Yellow solid). Yield (24.8 mg, 69%). mp 151–152 °C. ^1H NMR (400 MHz, CDCl_3) δ = 7.99 (d, $J = 7.5$ Hz, 1H), 7.72 (d, $J = 6.1$ Hz, 1H), 7.64 (d, $J = 8.1$ Hz, 1H), 7.38–7.32 (m, 2H), 7.23–7.16 (m, 2H), 7.12–7.06 (m, 6H), 6.72 (s, 3H), 6.51 (m, 1H), 6.40 (m, 1H), 2.09 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ = 136.34, 136.3, 134.9, 133.5,

133.4, 131.3, 129.4, 129.0, 128.4, 128.0, 127.9, 127.6, 126.6, 126.0, 125.9, 125.6, 124.8, 111.7, 109.5, 21.0 ppm; MS (EI, 70 eV) *m/z* 91, 165, 207, 239, 359; HRMS (ESI) *m/z* calcd for C₂₇H₂₁NNa [M + Na]⁺, 382.1558, found 382.1566; IR (KBr) 2991, 1764, 1595, 1514, 1477, 1377, 1242, 1056, 753 cm⁻¹.

2-Methyl-3,5-diphenyl-1-(*p*-tolyl)-1*H*-pyrrole (3oa).²¹ (Yellow solid). Yield (17.1 mg, 69%). mp 137–139 °C. ¹H NMR (400 MHz, CDCl₃) δ = 7.52 (d, *J* = 7.4 Hz, 2H), 7.41 (t, *J* = 7.4 Hz, 2H), 7.16 (m, 10H), 6.57 (s, 1H), 2.39 (s, 3H), 2.25 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 137.4, 137.0, 136.6, 133.9, 133.3, 129.7, 128.4, 128.1, 128.0, 127.9, 125.8, 125.4, 122.6, 118.9, 116.9, 109.1, 21.2, 12.4 ppm; MS (EI, 70 eV) *m/z* 91, 117, 146, 161, 191, 323; IR (KBr) 3026, 2924, 1732, 1598, 1513, 1452, 1379, 754.698 cm⁻¹.

1-(*p*-Tolyl)-1*H*-pyrrole (4a).²² (Yellow solid). Yield (12.3 mg, 78%). mp 84–85 °C. ¹H NMR (400 MHz, CDCl₃) δ = 7.38–7.22 (m, 5H), 7.09 (s, 2H), 6.36 (s, 2H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 137.5, 134.3, 129.0, 119.5, 118.4, 109.0, 19.8 ppm; MS (EI, 70 eV) *m/z* 115, 129, 157; IR (KBr) 2919, 2851, 1652, 1588, 1467, 1262, 1092, 1022, 801, 753 cm⁻¹.

1-(4-Chlorophenyl)-1*H*-pyrrole (4b).²³ (Yellow solid). Yield (11.9 mg, 67%). mp 90 °C. ¹H NMR (400 MHz, CDCl₃) δ = 7.39 (d, *J* = 8.7 Hz, 2H), 7.33 (d, *J* = 8.7 Hz, 2H), 7.05 (s, 2H), 6.36 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ = 139.3, 131.1, 129.6, 121.6, 119.3, 110.8 ppm; MS (EI, 70 eV) *m/z* 115, 142, 177; IR (KBr) 2921, 2862, 1639, 1506, 1467, 1074, 826, 729 cm⁻¹.

2-Phenyl-1-(*m*-tolyl)-2,5-dihydro-1*H*-pyrrole (5). (Yellow oil). Yield (13.4 mg, 57%). ¹H NMR (400 MHz, CDCl₃) δ = 7.32–7.26 (m, 4H), 7.22 (d, *J* = 6.4 Hz, 1H), 7.02 (t, *J* = 7.5 Hz, 1H), 6.47 (d, *J* = 7.3 Hz, 1H), 6.36 (s, 1H), 6.31 (d, *J* = 8.2 Hz, 1H), 5.96–5.91 (m, 1H), 5.85 (d, *J* = 6.0 Hz, 1H), 5.40 (s, 1H), 4.47 (dd, *J* = 14.0, 5.0 Hz, 1H), 4.25 (d, *J* = 13.9 Hz, 1H), 2.24 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ = 146.5, 142.8, 138.8, 132.5, 128.9, 128.8, 127.1, 126.2, 124.2, 117.1, 112.85, 109.5, 69.7, 56.2, 21.8 ppm; MS (EI, 70 eV) *m/z* 91, 118, 143, 158, 194, 235; HRMS (ESI) *m/z* calcd for C₁₇H₁₈N [M + H]⁺, 236.1433, found 236.1434; IR (KBr) 3055, 2925, 1708, 1594, 1494, 1357, 758, 699 cm⁻¹.

ASSOCIATED CONTENT

Supporting Information

¹H and ¹³C NMR spectra of all synthesized compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*E-mail: jianghf@scut.edu.cn.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We are grateful to the National Basic Research Program of China (973 Program) (2011CB808600), the National Natural Science Foundation of China (21172076 and 21202046), the Guangdong Natural Science Foundation (10351064101000000), and the Fundamental Research Funds for the Central Universities (2014ZP0004 and 2014ZZ0046).

REFERENCES

- (a) Liu, C.; Zhang, H.; Shi, W.; Lei, A. *Chem. Rev.* **2011**, *111*, 1780. (b) Cho, S. H.; Kim, J. Y.; Kwak, J.; Chang, S. *Chem. Soc. Rev.* **2011**, *40*, 5068. (c) Shi, Z.; Zhang, C.; Tang, C.; Jiao, N. *Chem. Soc. Rev.* **2012**, *41*, 3381. (d) Gulzar, N.; Schweitzer-Chaput, B.; Klussmann, M. *Catal. Sci. Technol.* **2014**, *4*, 2778. (e) Yeung, C. S.; Dong, V. M. *Chem. Rev.* **2011**, *111*, 1215.
- (a) Rauf, W.; Brown, J. M. *Chem. Commun.* **2013**, *49*, 8430. (b) Lyons, T. W.; Sanford, M. S. *Chem. Rev.* **2010**, *110*, 1147. (c) Wu,

W.; Jiang, H. *Acc. Chem. Res.* **2012**, *45*, 1736. (d) Gligorich, K. M.; Sigman, M. S. *Chem. Commun.* **2009**, 3854.

(3) Dieck, H. A.; Heck, R. F. *J. Org. Chem.* **1975**, *40*, 1083. (4) (a) Grimster, N. P.; Gauntlett, C.; Godfrey, C. R. A.; Gaunt, M. J. *Angew. Chem., Int. Ed.* **2005**, *44*, 3125. (b) Lindh, J.; Enquist, P.-A.; Pilotti, Å.; Nilsson, P.; Larhed, M. *J. Org. Chem.* **2004**, *69*, 5212. (c) Yoo, K. S.; Yoon, C. H.; Jung, K. W. *J. Am. Chem. Soc.* **2006**, *128*, 16384. (d) Andappan, M. M. S.; Nilsson, P.; Schenck, H.; Larhed, M. *J. Org. Chem.* **2007**, *72*, 7957. (e) Andappan, M. M. S.; Nilsson, P.; Larhed, M. *Mol. Diversity* **2003**, *7*, 97. (f) Du, X.; Suguro, M.; Hirabayashi, K.; Mori, A.; Nishikata, T.; Hagiwara, N.; Kawata, K.; Okeda, T.; Wang, H. F.; Fugami, K.; Kosugi, M. *Org. Lett.* **2001**, *3*, 3313.

(5) Liao, L.; Sigman, M. S. *J. Am. Chem. Soc.* **2010**, *132*, 10209.

(6) (a) Zhang, T.-K.; Mo, D.-L.; Dai, L.-X.; Hou, X.-L. *Org. Lett.* **2008**, *10*, 3689. (b) Huang, L.; Wang, Q.; Wu, W.; Jiang, H. *Adv. Synth. Catal.* **2014**, *356*, 1949.

(7) (a) Ruan, J.; Li, X.; Saidi, O.; Xiao, J. *J. Am. Chem. Soc.* **2008**, *130*, 2424. (b) Su, Y.; Jiao, N. *Org. Lett.* **2009**, *11*, 2980.

(8) (a) Delcamp, J. H.; Gormisky, P. E.; White, M. C. *J. Am. Chem. Soc.* **2013**, *135*, 8460. (b) Zheng, C.; Wang, D.; Stahl, S. S. *J. Am. Chem. Soc.* **2012**, *134*, 16496.

(9) (a) Chen, M.; Wang, J.; Chai, Z.; You, C.; Lei, A. *Adv. Synth. Catal.* **2012**, *354*, 341. (b) Mei, T.-S.; Werner, E. W.; Burckle, A. J.; Sigman, M. S. *J. Am. Chem. Soc.* **2013**, *135*, 6830. (c) Zhu, C.; Falck, J. R. *Angew. Chem., Int. Ed.* **2011**, *50*, 6626. (d) Zhang, L.; Dong, C.; Ding, C.; Chen, J.; Tang, W.; Li, H.; Xu, L.; Xiao, J. *Adv. Synth. Catal.* **2013**, *355*, 1570. (e) Trejos, A.; Fardost, A.; Yahiaoui, S.; Larhed, M. *Chem. Commun.* **2009**, *48*, 7587.

(10) (a) Gulevich, A. V.; Dudnik, A. S.; Chernyak, N.; Gevorgyan, V. *Chem. Rev.* **2013**, *113*, 3084. (b) Trofimov, B. A.; Sobenina, L. N.; Demenev, A. P.; Mikhaleva, A. I. *Chem. Rev.* **2004**, *104*, 2481. (c) Walsh, C. T.; Garneau-Tsodikova, S.; Howard-Jones, A. R. *Nat. Prod. Rep.* **2006**, *23*, 517. (d) Portevin, B.; Tordjman, C.; Pastoureaux, P.; Bonnet, J.; Nanteuil, G. D. *J. Med. Chem.* **2000**, *43*, 4582. (e) Lewis, J. R. *JAMA, J. Am. Med. Assoc.* **1981**, *246*, 377. (f) Fan, H.; Peng, J.; Hamann, M. T.; Hu, J.-F. *Chem. Rev.* **2008**, *108*, 264.

(11) (a) Toh, K. K.; Wang, Y.-F.; Ng, E. P. J.; Chiba, S. *J. Am. Chem. Soc.* **2011**, *133*, 13942. (b) Pan, B.; Wang, C.; Wang, D.; Wu, F.; Wan, B. *Chem. Commun.* **2013**, *49*, 5073. (c) Rakshit, S.; Patureau, F. W.; Glorius, F. *J. Am. Chem. Soc.* **2010**, *132*, 9585. (d) Trost, B. M.; Lumb, J.-P.; Azzarelli, J. M. *J. Am. Chem. Soc.* **2011**, *133*, 740. (e) Zhao, M.; Wang, F.; Li, X. *Org. Lett.* **2012**, *14*, 1412. (f) Li, Q.; Fan, A.; Lu, Z.; Cui, Y.; Lin, W.; Jia, Y. *Org. Lett.* **2010**, *18*, 4006. (g) Gorin, D. J.; Davis, N. R.; Toste, F. D. *J. Am. Chem. Soc.* **2005**, *127*, 11260. (h) Zhang, M.; Fang, X.; Neumann, H.; Beller, M. *J. Am. Chem. Soc.* **2013**, *135*, 11348. (i) Xin, X.; Wang, D.; Li, X.; Wan, B. *Angew. Chem., Int. Ed.* **2012**, *51*, 1693.

(12) (a) Huang, L.; Wang, Q.; Qi, J.; Wu, X.; Huang, K.; Jiang, H. *Chem. Sci.* **2013**, *4*, 2665. (b) Huang, L.; Qi, J.; Wu, X.; Huang, K.; Jiang, H. *Org. Lett.* **2013**, *15*, 2330. (c) Huang, L.; Qi, J.; Wu, X.; Wan, W.; Jiang, H. *Chem.—Eur. J.* **2013**, *19*, 15462. (d) Huang, L.; Wang, Q.; Wan, W.; Jiang, H. *J. Org. Chem.* **2014**, *79*, 7734. (e) Huang, L.; Wang, Q.; Wu, W.; Jiang, H. *ChemCatChem* **2014**, *6*, 561.

(13) (a) Majumdar, K. C.; Chattopadhyay, B.; Samanta, S. *Tetrahedron Lett.* **2009**, *50*, 3178. (b) Jang, T.-S.; Ku, W.; Jang, M. S.; Keum, G.; Kang, S. B.; Chung, B. Y.; Kim, Y. *Org. Lett.* **2006**, *8*, 195. (c) Hatano, M.; Suzuki, S.; Ishihara, K. *J. Am. Chem. Soc.* **2006**, *128*, 9998.

(14) Nishio, T. *Helv. Chim. Acta* **1998**, *81*, 1207.

(15) Kel'in, V. A.; Sromek, W. A.; Gevorgyan, V. *J. Am. Chem. Soc.* **2001**, *123*, 2074.

(16) Bilodeau, F.; Brochu, M.; Guimond, N.; Thesen, K. H.; Forgione, P. *J. Org. Chem.* **2010**, *75*, 1550.

(17) Shibat, I.; Kato, H.; Yasuda, M.; Baba, A. *J. Organomet. Chem.* **2007**, *692*, 604.

(18) Katritzky, A. R.; Chang, H.-X.; Verin, S. V. *Tetrahedron Lett.* **1995**, *36*, 343.

(19) Lee, H.; Kim, B. H. *Tetrahedron* **2013**, *69*, 6698.

- (20) Huerta, G.; Fomina, L.; Rumsh, L.; Zolotukhin, M. G. *Polym. Bull.* **2006**, *57*, 433.
- (21) Liu, X.; Hao, L.; Lin, M.; Chen, L.; Zhan, Z. *Org. Biomol. Chem.* **2010**, *8*, 3064.
- (22) Reddy, V. P.; Kumar, A. V.; Rao, K. R. *Tetrahedron Lett.* **2011**, *52*, 777.
- (23) Yang, H.; Xi, C.; Miao, Z.; Chen, R. *Eur. J. Org. Chem.* **2011**, *3353*.